SciELO - Scientific Electronic Library Online

 
vol.13 número6Avaliação do potencial patogénico dos genes sabA e hopZ de estirpes de Helicobacter Pylori isoladas numa população portuguesaAscite de Etiologia pouco frequente índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Jornal Português de Gastrenterologia

versão impressa ISSN 0872-8178

J Port Gastrenterol. v.13 n.6 Lisboa nov. 2006

 

Programa de vigilância em famílias com Síndroma de Lynch – a eficácia da medicina preventiva

S. Mão de Ferro*, P. Lage*, A. Suspiro*, J. Pereira da Silva*, I. Claro*, P. Fidalgo*, P. Rodrigues*, B. Filipe**, I. Francisco**, P. Chaves**, C. Albuquerque***, C. Nobre Leitão*

  

Resumo

Introdução: A Sindroma de Lynch (SL) confere um elevado risco de desenvolvimento de cancro do cólon e recto (CCR). A vigilância é eficaz na prevenção do CCR em indivíduos em risco.

Objectivos: Avaliar o impacto da colonoscopia na detecção de lesões em indivíduos pertencentes a famílias com SL.

Materiais e Métodos: 165 indivíduos assintomáticos, submetidos a vigilância, de acordo com os grupos: GI- Mutação para SL (n=33), GII- Critérios de Amesterdão (n=95), GIII- Critérios de Amesterdão excepto idade (n=37). Programada colonoscopia anual para GI e bienal para GII e GIII.

Resultados: No primeiro exame foram detectados adenomas em 28 (15,8%) indivíduos. A detecção de adenomas foi apenas influenciada pela idade (p=0,02). As lesões localizaram-se mais frequentemente no cólon direito em GI e GII (p=0,05). Diagnosticaram-se CCR em 7 (4,2%) indivíduos (GI-3, GII-3, GIII-1, idade=45, 31-71 anos), 5 localizados à direita, 4 T1N0M0, 2 T3N0M0, 1 T3N2M1. Efectuaram-se 123 exames de vigilância (77 indivíduos). Detectaram-se adenomas em 13 (23,4%) indivíduos. Não houve CCR de intervalo nem nos exames de vigilância.

Conclusões: Indivíduos com SL apresentaram uma elevada prevalência e incidência de adenomas e CCR, em idades jovens. A ausência do critério de idade não parece determinante para o tipo de vigilância a implementar.

 

Summary

Introduction: Hereditary non-polyposys colorectal cancer (HNPCC) syndrome confers a high risk of colorectal cancer (CRC) development. Colonoscopic surveillance is effective in preventing mortality from CRC.

Aims: To evaluate the incidence and prevalence of colorectal tumours in asymptomatic individuals with HNPCC who undergo screening colonoscopies.

Methods: 165 asymptomatic individuals divided in 3 groups. GI- MMR mutation (n=33), GII- Amsterdam Criteria (n=95), GIII- Amsterdam criteria except for older age at onset (n=35). Surveillance was performed annually for GI and every 2 years for GII and GIII.

Results: In the first colonoscopy we detected adenomas in 26 (15.8%) patients. Adenoma detection was associated only with older age (p=0.02). Patients from GI and GII were more likely to have proximal lesions (p=0.05). Seven (4.2%) patients had CRC (G1=3, GII=3, GIII=1; mean age: 45 years – range: 31-71): four T1N0M0, two T3N0M0 and one T3N2M1. Seventy-seven individuals had follow-up colonoscopies. We detected adenomas in 13 (23.4%) patients – an incidence of 0.13 adenomas/individual/year. No CRC was detected at follow up, nor did interval cancers occur.

Conclusions: Asymptomatic individuals with a family history of CRC present a high incidence and prevalence and a young onset of colorectal tumours. Families that do not fulfil the Amsterdam criteria due to late age at onset seem to benefit from the same surveillance that is applied to patients with HNPCC.

 

 

Texto Completo disponível apenas em PDF

Full text only available in PDF format

 

 

Bibliografia

 

1. Hampel H, Frankel W, Martin E, Kanduja K, Kuebler P, Nakagawa H, et al. Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). N Eng J Med 2005; 352: 1851-60.        [ Links ]

2. Aaltonen LA, Salovaara R, Kristo P, Can-zian F, Hemminki A, Peltomaki P, et al. Incidente of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Eng J Med 1998; 338: 1481-7.

3. Lynch HT, Smyrk TC. Hereditary colon cancer. Semin Oncol. 1999; 26: 478-84.

4. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RD, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instabilioty in colorectal cancer. Cancer Res 1998;58:5248-57.

5. Vasen HF, Mecklin JP, Kahn PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991:34;424-5.

6. Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999;116:1453-6.

7. Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer mutations in MSH2 and MLH1. J Med Genet 2000;37:641-5.

8. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer and microssatellite instability. J Natl Cancer Inst 2004;96:261-8.

9. Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108: 1405-11.

10. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonnen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-34.

11. Fuchs CS, Giovannuci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, et al. Family history increases the risk of colorectal cancer. Gastroenterology 1995; 109: 1015-9.

12. Winawer S, Zauber AG, O´Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. National Polyp Study Workgroup. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Eng J Med 1993;328:901-6.

13. Syngal S, Fox EA, Li C, Dovidio M, Eng C, Kolodner RD, et al. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: Implications for clinical predisposition testing. JAMA 1999;282(2):247-53.

14. Lovett E. Family studies in cancer of the colon and rectum. Br J Surg 1976;63:13-8.

15. Vasen HFA, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, et al. A cost-effectiveness análisis of colorectal cancer screening of hereditary non-polyposiis colorectal carcinoma gene carriers. Cancer 1998;82:1632-7.

16. Ramsey SD, Clarke l, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microssatelite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Inter Med 2001;135:577-88.

17. Syngal S, Weeks JC, Schrag D, Gasber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. An Intern Med 1998; 129: 787-96.

18. Lynch H. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis colon rectum 1996; 39: 109-10

19. Goldberg PA, Madden MV, Harocopos C, Felix R, Westbrook C, Ramesar RS. In a resource-poor country, mutation identification has the potential to reduce the cost of family management for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum 1998; 41: 1250-5.

20. Dove-Edwin I, Sasiene P, Adams J, Tho-mas H. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ, 2005; 331: 1047.

21. Lanspa S, Lynch H, Smyrk T, Staryhorn P, Watson P, Lynch JF, et al. Colorectal adenomas in the Lynch syndromes. Results of a colonoscopy screening programme. Gastroenterology 1990;98:1117-22.

22. Lijegren, Lindblom A, Rotsein S, Nilsson B, Jaramillo E. Prevalence and incidence of hyperplastic polyps and adenomas in familial colorectal cancer: correlation between the two types of colon polyps. Gut 2003;52:1140-7.

23. De Jong A, Morreau H, van Puijenbroek M, Eilers PH, Wijnen J, Nagengast FM, et al. The role of mmismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology 2004;126:42-8.

24. Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut 2002;50:228-34.

25. Suspiro A, Mão de Ferro S, Lage P, Claro I, Chaves P, Rodrigues P, et al. Rastreio endoscópico em familiares de doentes com cancro do cólon e recto. GE-J Port Gastrenterol 2003,10:273-9.

26. Pinto A, Chaves P, Claro I, Lage P, Suspiro A, Chagas C, et al. Rastreio do carcinoma do cólon e recto. Importância da sigmoidoscopia flexível. GE- J Port Gastrenterol 1997;4:77-83.

27. Liebermann DA, Weiss DG for the Veterans Affairs Cooperative Study Group 380. One time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Eng J Med 2001;345:555-60.

28. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996;69:38-43.

29. Vasen HF. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Fam Cancer 2005;4:219-25.

30. Vasen HF, Taal BG, Nagengast FM, Griffioen G, Menko FH, Kleibeuker JH, et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 1995;31A:1145-8.

31. Winawer SJ, Fletcher RH, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening: clinical guidelines and rationale: Evidence based on new evidence. Gastroenterology 2003;124(2):544-60.

32. Winawer A, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, et al. National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Eng J Med 1993; 329: 1977-81.

33. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, et al. Recomendations for follow-up care of individuals with as inherited predisposition to cancer. I- Hereditary non-polyposis colorectal cancer. JAMA 1997; 277: 915-919.

34. Vasen HF, Nagengast FM, Kahn PM. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995; 345: 1183-4.

35. Lynch H, de la Clapelle A. Hereditary colorectal cancer. N Eng J Med 2003; 348: 919-32.

36. Johnson PM, Gallinger S, McLoud RS. Surveillance colonoscopy in individuals at risk for hereditary nonpolyposis colorectal cancer: an evidence-based review. Dis Colon Rectum 2006; 49: 80-93.

 

 

Correspondência:

Susana Mão de Ferro

Serviço de Gastrenterologia - IPOLFG.EPE,

R. Prof Lima Basto 1500 - Lisboa

Tel.: 217200422

e-mail: smaodeferro@gmail.com

 

(*) Serviço de Gastrenterologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, Portugal.

(**) Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, Portugal.

(***) Centro de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, Portugal.

 

 

Recebido para publicação: 11/05/2006

Aceite para publicação: 17/10/2006